Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cristina Poveda

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
American Journal of Veterinary Research|December 6, 2023
Intramuscular but not nebulized administration of a mRNA vaccine against Rhodococcus equi stimulated humoral immune responses in neonatal foalsRebecca M Legere, Cristina Poveda, Jeannine A Ott, et al.
Biochimica Et Biophysica Acta. General Subjects|March 18, 2021
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidateWen-Hsiang Chen, Junfei Wei, Rakhi Tyagi Kundu, et al.
Protein Expression and Purification|October 24, 2021
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidateWen-Hsiang Chen, Jeroen Pollet, Ulrich Strych, et al.
Vaccine|May 14, 2022
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernJeroen Pollet, Ulrich Strych, Wen-Hsiang Chen, et al.
Biorxiv : the Preprint Server for Biology|November 11, 2020
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Human Vaccines & Immunotherapeutics|April 13, 2021
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in miceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2021
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernJeroen Pollet, Ulrich Strych, Wen-Hsiang Chen, et al.
Vaccines|October 28, 2023
A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2Syamala Rani Thimmiraju, Rakesh Adhikari, Maria Jose Villar, et al.
Expert Review of Vaccines|May 30, 2023
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global accessPeter J Hotez, Rakesh Adhikari, Wen-Hsiang Chen, et al.
Annals of the New York Academy of Sciences|March 8, 2021
Autoantibodies against the immunodominant sCha epitope discriminate the risk of sudden death in chronic Chagas cardiomyopathyHéctor O Rodríguez-Angulo, Andrés Lamsfus-Calle, Javier Isoler-Alcaráz, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
American Journal of Veterinary Research|December 6, 2023
Intramuscular but not nebulized administration of a mRNA vaccine against Rhodococcus equi stimulated humoral immune responses in neonatal foalsRebecca M Legere, Cristina Poveda, Jeannine A Ott, et al.
Biochimica Et Biophysica Acta. General Subjects|March 18, 2021
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidateWen-Hsiang Chen, Junfei Wei, Rakhi Tyagi Kundu, et al.
Protein Expression and Purification|October 24, 2021
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidateWen-Hsiang Chen, Jeroen Pollet, Ulrich Strych, et al.
Vaccine|May 14, 2022
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernJeroen Pollet, Ulrich Strych, Wen-Hsiang Chen, et al.
Biorxiv : the Preprint Server for Biology|November 11, 2020
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Human Vaccines & Immunotherapeutics|April 13, 2021
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in miceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2021
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernJeroen Pollet, Ulrich Strych, Wen-Hsiang Chen, et al.
Vaccines|October 28, 2023
A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2Syamala Rani Thimmiraju, Rakesh Adhikari, Maria Jose Villar, et al.
Expert Review of Vaccines|May 30, 2023
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global accessPeter J Hotez, Rakesh Adhikari, Wen-Hsiang Chen, et al.
Annals of the New York Academy of Sciences|March 8, 2021
Autoantibodies against the immunodominant sCha epitope discriminate the risk of sudden death in chronic Chagas cardiomyopathyHéctor O Rodríguez-Angulo, Andrés Lamsfus-Calle, Javier Isoler-Alcaráz, et al.
Pageof 6